What Emgality Treats
Emgality (galcanezumab-gnlm) is an injectable CGRP antagonist approved by the FDA to prevent migraines in adults. It targets calcitonin gene-related peptide, a protein involved in migraine attacks, reducing their frequency.[1]
How Emgality Is Used
Patients self-administer it monthly via subcutaneous injection using a prefilled autoinjector. A loading dose of 240 mg (two 120 mg injections) starts treatment, followed by 120 mg monthly. It's for episodic (4-14 headache days/month) or chronic migraines (15+ headache days/month).[1]
How It Differs from Acute Migraine Drugs
Unlike triptans or NSAIDs for stopping active migraines, Emgality is preventive only—it doesn't treat attacks in progress. Doctors often pair it with acute meds for breakthrough pain.[1]
Common Side Effects Patients Report
Most experience mild injection-site reactions (pain, redness). Serious risks include allergic reactions or hypersensitivity. No black-box warnings; constipation or high blood pressure occur rarely.[1]
Who Makes Emgality and What's the Cost
Eli Lilly manufactures it. List price is about $800 per monthly dose before insurance or discounts; patient assistance programs can lower it for eligible users.[1]
When Does Emgality's Patent Expire
Key U.S. patents on galcanezumab expire around 2030-2033, with some formulation patents to 2036. Challenges from generics are pending; biosimilars unlikely due to its monoclonal antibody structure. Check DrugPatentWatch.com for litigation updates.[2]
[1]: FDA Label - Emgality (galcanezumab-gnlm) injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdf
[2]: DrugPatentWatch.com - Emgality Patents. https://www.drugpatentwatch.com/p/tradename/EMGALITY